Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Latest News on PHIO

Apr 9, 2025, 7:45 AM EDT - 12 days ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 18 days ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 20 days ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 6 weeks ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 6 weeks ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 26, 2025, 7:45 AM EST - 7 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Feb 20, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 3 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 3 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 3 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 3 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 3 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 3 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 3 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 3 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 4 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 4 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 4 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 4 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 4 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 5 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 5 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 5 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 6 months ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 6 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 6 months ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 7 months ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 7 months ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 8 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 8 months ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 1, 2024, 8:00 AM EDT - 9 months ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Jul 12, 2024, 8:00 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 8, 2024, 8:00 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 5, 2024, 8:00 AM EDT - 10 months ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 2, 2024, 11:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Reverse Stock Split

Jun 18, 2024, 7:30 AM EDT - 10 months ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

May 28, 2024, 7:30 AM EDT - 11 months ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 23, 2024, 5:00 PM EDT - 11 months ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 17, 2024, 9:00 AM EDT - 1 year ago

Phio Pharmaceuticals Secures New Investor

May 15, 2024, 1:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

May 9, 2024, 5:25 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

Apr 22, 2024, 1:10 PM EDT - 1 year ago

Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

Apr 3, 2024, 7:30 AM EDT - 1 year ago

National Spotlight Features Phio's Innovative RNAi Technology Platform

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Mar 13, 2024, 2:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

Market Cap	13.04M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	0.57
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,636,800
Avg Vol	3,548,886
Day's Range	N/A - N/A
Shares Out	4.78M
Stochastic %K	81%
Beta	1.09
Analysts	Strong Sell
Price Target	$4.00